Mizuho maintains Haemonetics Outperform rating
Benzinga reports that Mizuho maintained its Outperform rating on Haemonetics.
Story updates
06:13:11 PM UTC
SquawkNews
Haemonetics Price Target Raised to $140.00/Share From $95.00 by Mizuho
06:28:36 PM UTC
SquawkNews
Haemonetics Is Maintained at Outperform by Barrington Research